Guggenheim downgraded Rapt Therapeutics (RAPT) to Neutral from Buy after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Rapt Therapeutics downgraded to Hold from Buy at Clear Street
- GSK to Acquire RAPT Therapeutics in Cash Merger
- GSK to acquire Rapt Therapeutics for $58.00 per share
- M&A News: GSK Bets Big on Food Allergy Drugs with $2.2B RAPT Therapeutics Deal